ArticlePloS one2025
Using machine learning for detection of Parkinson's disease and mild cognitive impairment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease is a movement disorder featuring motor symptoms and cognitive decline, which can manifest as mild cognitive impairment. The incidence of mild cognitive impairment increases with disease progression, and Parkinson's disease can cause significant disability, therefore, identification of Parkinson's disease and mild cognitive impairment in Parkinson's disease is imperative. Neuroimaging and biofluid biomarkers have been studied separately, however, research suggests that combining biomarkers may improve detection.
objectivesWe aimed to investigate using machine learning whether a combination of neuroimaging and biofluid biomarkers would result in more effective identification of Parkinson's disease and mild cognitive impairment.
methodsUtilizing the Parkinson's Progression Markers Initiative dataset, we applied two different machine learning approaches, support vector machine and random forest, to explore combinations of neuroimaging and cerebrospinal fluid biomarkers for detection.
resultsOverall, both machine learning techniques had an equivalent performance. In general, in those models for detecting Parkinson's disease, DaT-SPECT performed better than biofluid biomarkers. In models for detecting Parkinson's disease patients with mild cognitive impairment, combining DaT-SPECT with phosphorylated-tau-181 resulted in higher accuracy, outperforming DaT-SPECT alone.
conclusionsClassification for Parkinson's disease and mild cognitive impairment may be improved by combining neuroimaging with biofluid biomarkers through machine learning models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.